LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Erasca Inc

Затворен

1.63 3.82

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.62

Максимум

1.63

Ключови измерители

By Trading Economics

Приходи

1.3M

-31M

Служители

103

EBITDA

-750K

-36M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+204.88% upside

Дивиденти

By Dow Jones

Следващи печалби

10.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

25M

419M

Предишно отваряне

-2.19

Предишно затваряне

1.63

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Erasca Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.08.2025 г., 16:11 ч. UTC

Значими двигатели на пазара

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15.08.2025 г., 22:22 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

15.08.2025 г., 22:22 ч. UTC

Пазарно говорене

Target Is Falling Behind Its Peers -- Market Talk

15.08.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.08.2025 г., 20:33 ч. UTC

Пазарно говорене

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15.08.2025 г., 20:25 ч. UTC

Печалби
Придобивния, сливания и поглъщания

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15.08.2025 г., 20:24 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15.08.2025 г., 20:18 ч. UTC

Печалби

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15.08.2025 г., 19:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15.08.2025 г., 19:12 ч. UTC

Пазарно говорене

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15.08.2025 г., 18:32 ч. UTC

Пазарно говорене

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15.08.2025 г., 17:33 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15.08.2025 г., 17:23 ч. UTC

Пазарно говорене
Печалби

Deere's Earnings Appear to Be Troughing -- Market Talk

15.08.2025 г., 16:27 ч. UTC

Печалби

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15.08.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.08.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

15.08.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

15.08.2025 г., 16:05 ч. UTC

Придобивния, сливания и поглъщания

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15.08.2025 г., 15:52 ч. UTC

Придобивния, сливания и поглъщания

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15.08.2025 г., 15:36 ч. UTC

Пазарно говорене

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15.08.2025 г., 15:29 ч. UTC

Печалби

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15.08.2025 г., 15:29 ч. UTC

Придобивния, сливания и поглъщания

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15.08.2025 г., 15:28 ч. UTC

Печалби

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15.08.2025 г., 15:24 ч. UTC

Пазарно говорене

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15.08.2025 г., 15:08 ч. UTC

Пазарно говорене

Applied Materials Is Losing Share in Chips Business -- Market Talk

15.08.2025 г., 14:38 ч. UTC

Придобивния, сливания и поглъщания

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15.08.2025 г., 14:37 ч. UTC

Придобивния, сливания и поглъщания

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15.08.2025 г., 14:37 ч. UTC

Придобивния, сливания и поглъщания

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15.08.2025 г., 14:36 ч. UTC

Придобивния, сливания и поглъщания

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15.08.2025 г., 14:33 ч. UTC

Придобивния, сливания и поглъщания

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Erasca Inc Прогноза

Ценова цел

By TipRanks

204.88% нагоре

12-месечна прогноза

Среден 5 USD  204.88%

Висок 6 USD

Нисък 4 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Erasca Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

1.39 / 1.44Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Very Strong Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.